These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17146932)

  • 1. [Current opinions on the treatment of androgen-independent prostate cancer].
    Guan XX; Chen LB
    Zhonghua Nan Ke Xue; 2006 Nov; 12(11):1021-5. PubMed ID: 17146932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for androgen-independent prostate cancer.
    Gulley J; Figg WD; Dahut WL
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):49-57. PubMed ID: 16227960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the management of metastatic androgen-independent prostate cancer.
    Laber DA; Goetz H K; Bhupalam L
    J Ky Med Assoc; 2006 Feb; 104(2):65-9. PubMed ID: 16594572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H; Messing EM; Chang C
    Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of c-Jun and c-Fos expression in androgen-independent prostate cancer.
    Edwards J; Krishna NS; Mukherjee R; Bartlett JM
    J Pathol; 2004 Oct; 204(2):153-8. PubMed ID: 15378488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hedgehog signalling in androgen independent prostate cancer.
    Shaw G; Price AM; Ktori E; Bisson I; Purkis PE; McFaul S; Oliver RT; Prowse DM
    Eur Urol; 2008 Dec; 54(6):1333-43. PubMed ID: 18262716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms.
    Schröder FH
    Eur Urol; 2008 Jun; 53(6):1129-37. PubMed ID: 18262723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy of advanced prostatic carcinoma.
    Millikan RE
    Semin Oncol; 1999 Apr; 26(2):185-91. PubMed ID: 10597729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bad expression influences time to androgen escape in prostate cancer.
    Teo K; Gemmell L; Mukherjee R; Traynor P; Edwards J
    BJU Int; 2007 Sep; 100(3):691-6. PubMed ID: 17542986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of hormonal refractory metastatic prostate cancer].
    Sengeløv L; Klarskov OP; Karlsson S
    Ugeskr Laeger; 2007 May; 169(20):1905-7. PubMed ID: 17553368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adapting treatment for prostate cancer according to risk of disease progression.
    Anderson J; Sternberg CN
    Crit Rev Oncol Hematol; 2008 Oct; 68 Suppl 1():S23-31. PubMed ID: 18752970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
    Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
    Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
    Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
    Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.